Fangsheng Pharmaceutical(SH:603998) Zheng Quan Shi Bao·2025-12-21 18:10Core Viewpoint - The company has successfully included its product, Yangxue Qufeng Zhitong Granules, in the National Medical Insurance Directory for 2025, indicating a significant milestone for its market presence and future sales potential [1]. Group 1: Event Announcement - The company will hold a product launch event for Yangxue Qufeng Zhitong Granules on December 21, 2025, from 9:00 to 12:00 at its R&D building in Changsha [1]. - Key attendees will include company executives and representatives from various securities firms and media [1]. Group 2: Business Operations and Strategy - The company has successfully launched two innovative traditional Chinese medicine products and plans to increase investment in this area, aiming to become a market leader in key therapeutic areas over the next three years [2][3]. - The company aims to create a product matrix with annual sales of 300-500 million yuan, focusing on innovative traditional Chinese medicines and complemented by other classic and high-end generic drugs [2]. - The company expects to achieve compound growth in performance over the next 3-5 years through product structure optimization and market expansion [2]. Group 3: Product Development and Market Expectations - Yangxue Qufeng Zhitong Granules has shown significant efficacy and safety in clinical trials for tension-type headaches, with plans to expand market access and brand building in 2026 [3][4]. - The company aims to cover over 500 public medical institutions and exceed the sales revenue of its previous product, Xuanqi Jianguo Pian, in 2026 [3]. Group 4: R&D and Innovation - The company has a diverse R&D pipeline covering various dosage forms and therapeutic areas, focusing on chronic diseases [4]. - Several innovative traditional Chinese medicine projects are in clinical trials, with approvals received for multiple products [4][5]. - The company emphasizes building a comprehensive R&D platform centered on innovative traditional Chinese medicine, with plans to explore chemical and biological innovations as well [4][5]. Group 5: Market Strategy and Policy Adaptation - The company is actively monitoring drug procurement policies and plans to leverage its product advantages to enhance market presence [6]. - The company is preparing for potential inclusion of its products in the essential drug list, which could positively impact its business [8]. Group 6: Talent and Incentives - The company has established a long-term incentive mechanism to attract and retain talent, with ongoing discussions about new incentive plans [7]. Group 7: Product Efficacy and Future Potential - Yangxue Qufeng Zhitong Granules addresses both headache symptoms and overall health, showing potential for expansion into other chronic pain areas [12][13]. - The product's formulation is designed to improve overall vitality and may have applications in treating various chronic pain conditions [12][13].